Summary
Twenty-five previously untreated patients with advanced adenocarcinoma of the upper gastrointestinal tract were treated with a combination of carboplatin and vinblastine. Two partial responses (duration three months and six months) were seen among 22 evaluable patients. Myelosuppression was the most common toxicity and was generally mild. The 8% response rate, (95% confidence interval 2 to 24%) observed in this study indicated that carboplatin-vinblastine has only modest activity in adenocarcinoma of the upper gastrointestinal tract. Although less toxic, this regimen appears to be less effective than previously reported cisplatin-containing regimens in adenocarcinoma of the upper GI tract.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Silverberg BS, Lubera JA: Cancer statistics, 1989. Ca-A Cancer Journal for Clinicians 39: 3–20, 1989
Macdonald JS, Gohmann J: Chemotherapy of advanced gastric cancer: present status, future prospects. Semin in Oncol 15: 42–49, 1988
Macdonald J, Schein P, Woolley P, Smythe T, Veno W, Hoth D, Smith F, Boiron M, Gissell-Brecht, Brunet R, Lagarde C: 5-fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 93: 533–536, 1980
Moertel C, Rubin J, O'Connell M, Schutt A, Wieand H: A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 4: 1053–1057, 1986
Kelsen D, Bajorin D: Phase I trial of carboplatin, vindesine or vinblastine, and bleomycin in advanced solid tumors. Cancer Invest (in press)
Einzig A, Kelsen DP, Cheng E: Phase II trial of carboplatin in patients with adenocarcinomas of the upper gastrointestinal tract. Cancer Treat Rep 69: 1453–1454, 1985
Wittes RE: Measures of Therapeutic Effect. Manual of Oncologic Therapeutics 1988/1989, p. 635.
Kelsen D, Heelan R, Coonley C, Bains M: Clinical and pathological assessment of response to therapy of patients with esophageal carcinoma. Am J Clin Oncol 6: 593–546, 1983
Lacave A, Izarzugaza I, Aparicio L, Pereda M, Garcia-Marco J, Buesa J: Phase II clinical trial of cisdichlorodiam-mineplatinum in gastric cancer. Am J Clin Oncol 6: 35–38, 1983
Beer M, Cocconi G, Ceci G: A phase II study of cisplatin in advanced gastric cancer. Eur J Cancer Clin Oncol 19: 717–720, 1983
Aabo K, Pedersen H, Rorth M: Cisplatin in the treatment of advanced gastric cancer: a phase II study. Cancer Treat Rep 69: 449–450, 1985
Leichman L, McDonald B, Dindogru A, Samson M, Vaitkevicius V: Cisplatin — an active drug in the treatment of disseminated gastric cancer. Cancer 53: 18–22, 1984
Cazap E, Gisselbrecht C, Smith F: Phase II trials of 5-FU, doxorubicin, and cisplatin in advanced, measurable adenocarcinoma of the lung and stomach. Cancer Treat Rep 70: 781–783, 1983
Wagener D, Burghouts J, van Dam F: A phase II trial of 5-fluorouracil, adriamycin and cisplatin (FAP) in advanced gastric cancer. (Abstr) Amer Soc Clin Oncol 2: 115, 1983
Robinson E, Haim N, Eppelbaum R, Cohen Y: Phase II trials in the treatment of advanced gastric cancer. (Abstr) Amer Soc Clin Oncol 4: 77, 1985
Author information
Authors and Affiliations
Additional information
The Gastrointestinal Oncology Service, Department of Medicine, and the Diagnostic RadiologyDepartment, Memorial Sloan-Kettering Cancer Center
Rights and permissions
About this article
Cite this article
Ginn, D., Kelsen, D., Eisenberger, M. et al. Phase II trial of carboplatin and vinblastine in adenocarcinoma of the stomach. Invest New Drugs 8, 321–324 (1990). https://doi.org/10.1007/BF00171847
Issue Date:
DOI: https://doi.org/10.1007/BF00171847